This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

AK2 V617F

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Janus kinases (JAKs) constitute a family of intracellular, non-receptor tyrosine kinases

  • is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2
    • are associated with their corresponding cell surface receptors and transduce signals from cytokines, as well as some hormones, such as growth hormone and prolactin
    • JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several genes involved in inflammatory, immune, and cancer conditions (1)
      • JAK1 seems to play a role in conditions such as:
        • pruritic dermatitis
        • allergic rhinitis
        • asthma
        • inflammatory bowel disease
      • inhibition of JAK1 and JAK2 molecules with JAK1 and JAK2 inhibitory activity have also provided therapeutic benefits in the treatment of:
        • rheumatoid arthritis
        • psoriasis
        • pruritis
      • inhibition of JAK3 several JAK3 selective inhibitors have been evaluated for their efficacy in the treatment of rheumatoid arthritis
      • TYK2 selective inhibitors may also be useful in the treatment of autoimmune diseases

JAK/STAT signaling in the pathogenesis of the myeloproliferative neoplasms (MPNs)

A central role for JAK/STAT signaling in the pathogenesis of the myeloproliferative neoplasms (MPNs) was discovered by identifying the somatically acquired JAK2V617F mutation in more than 95% of patients with polycythemia vera (PV) and over 50% of patients with essential thrombocytosis and primary myelofibrosis (2,3,4)

  • JAK2 V617F mutation is an acquired, somatic mutation present in the majority of patients with myeloproliferative cancer
  • the JAK2 V617F mutation may also be prevalent in individuals without overt signs of myeloproliferative cancer
  • activated JAK2 signaling by JAK2, CALR, and MPL mutations has become a focus for the development of targeted therapies for patients with MPN (3)
  • JAK2 inhibitors now represent a standard of clinical care for certain forms of MPN and offer important benefits for MPN patients

Reference:

  • Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011 Mar;96(3):450-3
  • Bader MS, Meyer SC. JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. Pharmaceuticals (Basel). 2022 Jan 28;15(2):160. doi: 10.3390/ph15020160. PMID: 35215273; PMCID: PMC8874480.
  • Schieber M, Crispino JD, Stein B. Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J. 2019 Sep 11;9(9):74. doi: 10.1038/s41408-019-0236-2. PMID: 31511492; PMCID: PMC6739355.
  • Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics. 2022 May 6;14(5):1001

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page